How do governments select vaccine-production partners when sector-specific capacity is incomplete? The COVID-19 pandemic made this question especially pressing, as vaccine nationalism constrained external supply and pushed middle-income states to expand domestic production despite unproven capacities. Tracing Argentina’s vaccine strategy from 2020 to 2022, this article develops the concept of projected capacity: a mechanism through which states infer potential capacity in one sector from firms’ resources, credibility, and structural position in another. Policymakers rely on proxies for vaccine-production capacity, including industrial legacies, firm–state familiarity, and alignment with health-sovereignty goals. State selection then provides firms with resources, alliances, and legitimacy, transforming projected capacity into sector-specific structural power. The article contributes to debates in political economy and public policy by showing that structural power is not only a pre-existing source of influence over the state; it can also be created through state decisions that select and support firms.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: